Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.51 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641800 | 0.92 | PLK1 (0.53) | PLK1ACAT1RARBPPARGPPARA | |
| SCHEMBL641666 | 0.88 | PLK1 (0.58) | PLK1ACAT1RARBNR1H4CACNA1H | |
| SCHEMBL642515 | 0.85 | LMNA (0.46) | RARBPPARGPPARANR1H4MCHR1 | |
| SCHEMBL642459 | 0.84 | NR1H4 (0.52) | PLK1RARBNR1H4 | |
| SCHEMBL642609 | 0.84 | PLK1 (0.55) | PLK1ACAT1RARBNR1H4CACNA1H | |
| SCHEMBL643690 | 0.83 | PLK1 (0.61) | PLK1ACAT1RARBNR1H4PLK3 | |
| SCHEMBL641397 | 0.82 | MCHR1 (0.48) | PLK1RARBPPARGPPARANR1H4 | |
| SCHEMBL643822 | 0.82 | PLK1 (0.57) | PLK1ACAT1RARBPPARGPPARA | |
| SCHEMBL643756 | 0.82 | PLK1 (0.57) | PLK1ACAT1RARBNR1H4PLK3 | |
| SCHEMBL642217 | 0.80 | PLK1 (0.55) | PLK1ACAT1RARBPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | claimed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | claimed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | claimed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | PLK1 1883/4885ACAT1 235/4885RARB 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.